

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Karl G. Csaky, et al.
Application No.: **10/588,884**
Filing Date: **August 27, 2007**
For: **Therapeutic Administration of the Scrambled Anti-Angiogenic Peptide C16Y**

Confirmation No.: **8820**
Group Art Unit: **1654**
Examiner: **Audet, Maury A.**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL REPLY PURSUANT TO 37 CFR § 1.116

In response to the final official action dated **January 24, 2011**, and supplemental to the reply filed March 22, 2011, reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

- Amendments to the Specification** begin on page _____ of this paper.
- Amendments to the Claims** are reflected in the listing of the claims which begins on page 2 of this paper.
- Amendments to the Drawings** begin on page _____ of this paper and include an attached replacement sheet.
- Remarks** begin on page 5 of this paper.
- The Commissioner is hereby authorized to charge any fee deficiency, charge any additional fees, or credit any overpayment of fees, associated with this application in connection with this filing, or any future filing, submitted to the U.S. Patent and Trademark Office during the pendency of this application, to Deposit Account No. 23-3050.